Anna Belser

Clinical Researcher

Data updated

Papers

9 publications

Trials

0 clinical trials

Research Footprint

Anna Belser appears in 9 tracked papers (2016–2023), most studied alongside Psilocybin, MDMA and Ayahuasca, across Depressive Disorders, Anxiety Disorders and Palliative & End-of-Life Distress.

Most-cited paper: Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: A randomized controlled trial (1678 citations).

Frequent co-authors: Gabrielle Agin-Liebes, Stephen Ross and James Guss.

Background & Research

Anna Belser (publishes as A. B. Belser) is a clinical researcher whose work centres on the experiential, therapeutic and procedural aspects of psychedelic-assisted psychotherapy. Her publications focus on qualitative and small-sample clinical investigations of psilocybin-assisted therapy for cancer-related distress and anxiety, including detailed case series and interpretative phenomenological analyses that probe patients' subjective responses and meaning-making processes. Belser has explored the phenomenology of mystical-type experiences both inside and outside pharmacologically induced states and has contributed to methodological and theoretical work on models of psychedelic-assisted psychotherapy.

Her contributions extend beyond patient narratives to the pragmatic organisation of therapeutic approaches: she is an author on contemporary assessments of psychedelic-assisted psychotherapy models and an introducer to EMBARK, a transdiagnostic, trans-drug psychotherapy framework. Belser's research is characterised by rigorous qualitative methods, careful attention to clinical context in oncology settings, and an orientation toward translating subjective patient experiences into frameworks that inform therapeutic practice and trial design.

Affiliations

Institutions, companies, and organisations Anna Belser is associated with.